Teva Pharmaceutical Industries (TEVA) Net Cash Flow (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Net Cash Flow for 18 consecutive years, with -$81.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 117.27% year-over-year to -$81.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 1434.78% YoY), and the FY2025 full-year result was $235.0 million, down 5.24% from the prior year.
• Net Cash Flow fell to -$81.0 million in Q2 2026 per TEVA's latest filing, from $202.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $1.4 billion in Q4 2025 and bottomed at -$1.6 billion in Q1 2025.
• Historically, Net Cash Flow has averaged $99.2 million across 5 years, with a median of $108.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow soared 1686.11% in 2023, then sank 1158.02% in 2025.
• Over 5 years, Net Cash Flow stood at $430.0 million in 2022, then surged by 111.4% to $909.0 million in 2023, then sank by 88.67% to $103.0 million in 2024, then soared by 1223.3% to $1.4 billion in 2025, then slumped by 105.94% to -$81.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$81.0 million, $202.0 million, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.